Patents by Inventor Ulrich Brinkmann

Ulrich Brinkmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-BIOTIN ANTIBODIES AND METHODS OF USE
    Publication number: 20150232577
    Abstract: The invention provides anti-biotin antibodies and methods of using the same.
    Type: Application
    Filed: December 19, 2014
    Publication date: August 20, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: ULRICH BRINKMANN, GUY GEORGES, MICHAEL GROTE, EIKE HOFFMANN
  • Antibodies against human angiopoietin 2
    Patent number: 9109027
    Abstract: The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: August 18, 2015
    Assignee: Hoffman-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Antibodies against human angiopoietin 2
    Patent number: 9073986
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: July 7, 2015
    Assignee: Hoffman-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Bi-specific digoxigenin binding antibodies
    Patent number: 9050375
    Abstract: This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: June 9, 2015
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Birgit Bramlage, Ulrich Brinkmann, Rebecca Croasdale, Simone Dill, Wilma Dormeyer, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann, Ludger Markus Ickenstein, Kerstin Jahn-Hofmann, Matthias John, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • MODIFIED PSEUDOMONAS EXOTOXIN A
    Publication number: 20150099707
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Werner Scheuer, Guy Georges
  • POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
    Publication number: 20150018229
    Abstract: The present invention relates to a polymorphic MRP-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein. Also provided is an antibody to the polypeptide, a transgenic animal, and a solid support comprising one or a plurality of the provided polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also provided. In addition, the invention relates to methods for producing a pharmaceutical composition, diagnosing a disease and detection of the polynucleotide.
    Type: Application
    Filed: May 13, 2014
    Publication date: January 15, 2015
    Inventors: Ulrich Brinkmann, Sven Hoffmeyer, Esther Mornhinweg
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20150004166
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 1, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
    Patent number: 8907069
    Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: December 9, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • Bispecific Anti ErbB3 / Anti cMet Antibodies
    Publication number: 20140135482
    Abstract: The present invention relates to bispecific antibodies against human ErbB-3 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: January 16, 2014
    Publication date: May 15, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Ulrich Brinkmann, Wilma Dormeyer, Eike Hoffmann, Christian Klein, Gerhard Niederfellner, Juergen Michael Schanzer, Jan Olaf Stracke, Claudio Sustmann, Pablo Umana
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 8703130
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: April 22, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20140065151
    Abstract: The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).
    Type: Application
    Filed: July 13, 2012
    Publication date: March 6, 2014
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
    Publication number: 20130309665
    Abstract: The present invention relates to a polymorphic MRP-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein. Also provided is an antibody to the polypeptide, a transgenic animal, and a solid support comprising one or a plurality of the provided polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also provided. In addition, the invention relates to methods for producing a pharmaceutical composition, diagnosing a disease and detection of the polynucleotide.
    Type: Application
    Filed: December 11, 2012
    Publication date: November 21, 2013
    Inventors: Ulrich Brinkmann, Sven Hoffmeyer, Esther Mornhinweg
  • PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE
    Publication number: 20130280279
    Abstract: The present invention relates to a pharmaceutical composition of complex of a monospecific antibody that binds to digoxigenin, and a digoxigenin-conjugated peptide, to the isolated or recovered complex as well as to a method of producing such complex or composition. Furthermore the use of such a pharmaceutical composition as a medicament is described.
    Type: Application
    Filed: June 27, 2013
    Publication date: October 24, 2013
    Inventors: Ulrich Brinkmann, Sebastian Dziadek, Eike Hoffmann
  • ACTIVATABLE BISPECIFIC ANTIBODIES
    Publication number: 20130266568
    Abstract: The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies.
    Type: Application
    Filed: February 21, 2013
    Publication date: October 10, 2013
    Inventors: ULRICH BRINKMANN, REBECCA CROASDALE, SILKE METZ, JUERGEN MICHAEL SCHANZER, CLAUDIO SUSTMANN, PABLO UMANA
  • BISPECIFIC ANTIBODIES COMPRISING A DISULFIDE STABILIZED - FV FRAGMENT
    Publication number: 20130267686
    Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 21, 2013
    Publication date: October 10, 2013
    Inventors: ULRICH BRINKMANN, ALEXANDER HAAS, SILKE METZ, JUERGEN MICHAEL SCHANZER
  • Antibodies against human angiopoietin 2
    Patent number: 8399626
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: March 19, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Antibodies against human angiopoietin 2
    Patent number: 8361747
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: January 29, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • TRIVALENT, BISPECIFIC ANTIBODIES
    Publication number: 20130022601
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: August 7, 2012
    Publication date: January 24, 2013
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20120321627
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: August 9, 2012
    Publication date: December 20, 2012
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES
    Publication number: 20120282280
    Abstract: This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 30, 2010
    Publication date: November 8, 2012
    Inventors: Birgit Bramlage, Ulrich Brinkmann, Rebecca Croasdale, Simone Dill, Wilma Dormeyer, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffman, Ludger Markus Ickenstein, Kerstin Jahn-Hofman, Matthias John, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke